fashion -WSS

fashion

author：focus 2025-09-30 19:25:32 - browse：5

Rod Nathan, Ali Urman, and Patrick Nosker on the 2024 Breakthrough Summit East stage. — From left, Rod Nathan, portfolio manager and partner of J. Goldman & Co.; ARK Invest senior analyst Ali Urman; and Patrick Nosker, director of research and partner at Affinity Asset Advisors, discuss biotech investment opportunities at the 2024 STAT Breakthrough Summit East. STAT

Following a blockbuster year of dealmaking and a recent uptick in biotech stocks, top investors see more good news on the horizon.

Driving the momentum? Economics 101.

Biotechs rely on borrowing capital, which is a more tenuous task when interest rates are high. But interest rates have most likely peaked, with Federal Reserve officials signaling earlier this week they expected to make three cuts this year. For public biotechnology startups that have been battered by the market in recent years, this is a very good thing, Rod Nathan, portfolio manager and partner of J. Goldman & Co., said on a panel at STAT’s Breakthrough Summit East in New York on Thursday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： What the airline industry can learn from medicine

hotspot

WSS

Sage hopes for a blockbuster in antidepressant now before FDA

Trump indictment: Who are the 'co

Chamber of Commerce, DOJ clash in court over drug prices

Why the drug industry's warnings on the IRA's impact fall short

Infectious disease expert Jeanne Marrazzo assumes Fauci role

The high personal cost of affirmative action for Black doctors

entertainment

fashion

explore

The high cost of giving birth even with insurance

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

At least 13 dead in Texas as scorching temps continue

How the messy conversation about Dolly changed bioethics

Tori Bowie and the unacceptable rates of Black maternal death

PBMs drew scrutiny in House hearing — and so did pharma

Medical records are filled with copy

Akili changes sales model for its ADHD video game treatment

United colonoscopy coverage change 'may cost lives,' doctors say

People with substance use disorder deserve online privacy

leisure time

Micronoma's microbiome cancer diagnostic approach under fire

No plane should take off without an EpiPen onboard

New safety details link Apellis eye drug to rare cases of blindness

FDA panel to weigh safety of artificial wombs for preterm births

White House Covid adviser calls on docs to combat misinformation

House panel takes first step toward fixing drug shortages

focus

knowledge

hotspot

hotspot